Product category:
Contract research
News Release from: Santaris Pharma | Subject: SPC3649
Edited by the Laboratorytalk Editorial
Team on 05 July 2007
Development of the first microRNA
medicine
The Danish National Advanced Technology Foundation (ATF) has awarded a grant of euro1.35 million to Santaris Pharma towards the development of the first ever drug targeted against a human microRNA
The drug candidate, SPC3649, is an antagonist of the liver-specific microRNA-122 and is being developed by Santaris in collaboration with the Centre for Biological Sequence Analyses at the Technical University of Denmark and the Department of Cellular and Molecular Medicine, University of Copenhagen This is the second award from the Danish ATF to the Santaris Pharma led consortium
This article was originally published on Laboratorytalk on 10 Dec 2003 at 8.00am (UK)
Related stories
New test could prevent more cervical cancer
A new test could be a more effective early warning system for preventing cervical cancer than the traditional smear according to Cancer Research UK scientists
Secrets of rogue cancer molecule revealed
Findings will help accelerate the search for potent and specific drugs that can target the protein and stop the growth and spread of these cancers
In 2006 the ATF made a grant to Santaris and the University of Copenhagen of euro1.3m, to support research in the rapidly evolving field of microRNA therapeutics.
MicroRNAs are a newly discovered class of tiny regulatory molecules which appear to control many biological processes within cells.
There is growing evidence that microRNAs are also associated with the onset and progression of many diseases.
Santaris Pharma's new drug candidate, SPC3649, targets a particular liver-expressed microRNA called miR-122.
Treatment of monkeys with the drug for only a few days results in a long-lasting reduction of blood cholesterol.
In addition, the drug blocks Hepatitis C virus growth in human liver cells.
Santaris Pharma is developing the compound as a potential new medicine for hyperlipidaemia and Hepatitis C infection.
Announcing the award, Sakari Kauppinen, Santaris Pharma's associate director of microRNA research, commented: "The entire field of molecular biology and medicine has been thrown wide open in recent years by the discovery of microRNAs.
"Santaris Pharma's LNA technology has unique advantages in developing potential breakthrough drugs acting on disease-associated microRNAs.
"We are delighted that the Danish Advanced Technology Foundation has recognised the scientific and commercial potential of our world leading position in this field.
"SPC3649 may well become the first microRNA antagonist drug to be tested in human clinical trials.".
• Santaris Pharma: contact details and other news
• Email this article to a colleague
• Register for the free Laboratorytalk email newsletter
• Laboratorytalk Home Page
Search the Pro-Talk network of sites
